Investment Insights
We partner with Hedge Funds, Private Equity houses, Venture Capital firms, Private / Angel investors, startups and entrepreneurs, providing timely and actionable research and insights that yield a competitive advantage.
From uncovering hidden investment opportunities and identifying emerging investment trends, to supporting a due-diligence process with crucial intelligence, we can provide timely and insightful recommendations for our clients.
Our insights and advisory focus on:
- Landscape analysis, including scientific and commercial due diligence
- Company / asset profiling, including addressable market size, growth drivers and expected growth, segmentation, value proposition etc.
- Decision-making opportunity / risk assessment, both for investors and their portfolio companies
- Other research and advisory, customized to our clients’ needs
We also provide fundraising services, by connecting entrepreneurs and companies who seek the all-important capital to kick-start or grow their venture with potential investors from our extensive network of contacts.
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, related to trending news from the investment space.
Want to make informed investments and capitalize on key opportunities? Let’s connect!
Reach out to info@lqventures.com to learn more about our strategic consulting and research capabilities.
October 24, 2025
Respiratory Today—October 24, 2025
October 24, 2025
Vaccines Today—October 24, 2025
October 24, 2025
Lucid Diligence Brief: Electra Therapeutics $183M Series C
October 23, 2025
Cardiovascular Video Recap—October 23, 2025
October 23, 2025
Lucid Diligence Brief: Takeda and Innovent global oncology partnership
October 23, 2025
Rare Disease Video Recap—October 23rd 2025
October 23, 2025
Cardiovascular Today—October 23, 2025
October 23, 2025
Rare Disease Today—October 23, 2025
October 23, 2025
Cell and Gene Therapy Today—October 23, 2025
October 22, 2025
Lucid Diligence Brief: Ipsen to acquire ImCheck Therapeutics
October 22, 2025
Neuroscience Today—October 22, 2025
October 22, 2025